Loading...
NPI 1891727657 · Waterbury, CT · Radiation Oncology Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
The Harold Leever Regional Cancer Center Inc is a radiation oncology clinic/center provider located in Waterbury, Connecticut. This profile covers 4 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | The Harold Leever Regional Cancer Center Inc |
| Address | 1075 Chase Pkwy |
| City | Waterbury |
| State | CT |
| ZIP | 06708 |
| Taxonomy | Radiation Oncology Clinic/Center |
| NPI Enumerated | July 6, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $921.3K |
| Medicare | $911K |
THE HAROLD LEEVER REGIONAL CANCER CENTER INC has specialized, imaging-heavy oncology operations: its top Medicare and Medicaid revenue drivers are PET/CT and PET radiopharmaceutical administration codes (78815, A9595, A9552), indicating the center primarily provides advanced diagnostic nuclear imaging services to guide cancer care rather than high volumes of therapeutic radiation delivery alone. The prominence of imaging and radiotracer codes suggests the site functions as a regional diagnostic PET/CT center integrated with radiation oncology services.
Revenue concentration on Medicare is highly focused: the precomputed top-3 Medicare codes account for 95.8% of total Medicare revenue, with 78815 alone representing $456.2K (50.1% of Medicare revenue) and A9595 contributing $348.5K (38.2%). This concentration implies most Medicare billings are tied to a small set of diagnostic PET/CT procedures and associated radiopharmaceuticals rather than a broadly diversified procedure mix.
Medicaid revenue is similarly concentrated: the precomputed top-3 Medicaid codes account for 93.5% of total Medicaid revenue, with 78815 overwhelmingly dominant at $800.4K (86.7% of Medicaid revenue). The Medicaid profile shows the center’s in‑state role is driven almost entirely by PET/CT imaging volume, with ancillary codes like 77336 and A9552 contributing only small shares of Medicaid revenue.
Payer mix is roughly balanced in scale but skewed in service intensity: total Medicare revenue is $911K and total Medicaid revenue is $921.3K, indicating the provider receives comparable overall revenue from both payers. However, the Medicaid revenue is more heavily concentrated in a single code (78815 at 86.7% of Medicaid revenue), whereas Medicare revenue, while also concentrated, is split more across 78815 and A9595 (combined representing 88.3% of Medicare revenue).
Competitive standing differs by payer and code: for Medicare, 78815 ranks #495 of 6566 providers nationally (92nd percentile), indicating the center has typical but unremarkable national volume for PET/CT claims, while A9595 ranks #64 of 528 providers nationally (88th percentile), showing relatively stronger specialty volume for that radiopharmaceutical at the national level. For Medicaid in Connecticut, 78815 ranks #8 of 24 in-state (70th percentile), placing the provider in the upper-middle tier of state peers for PET/CT volume but not dominant.
Operational scale and service mix suggest a diagnostic centerpiece supporting oncology workflows: high counts and payments for radiotracers (A9595, A9552) and PET/CT imaging (78815) across both payers indicate the facility is primarily capturing upstream diagnostic imaging revenue that likely feeds downstream treatment decisions, rather than generating most revenue from the array of radiation therapy delivery codes. This is reinforced by Medicaid therapy-planning and dosimetry codes (77336, 77334, 77300) appearing but contributing small shares of revenue.
Tenure is long-established: the provider’s NPI was enumerated on 2006-07-06 (~20 years ago), indicating two decades of participation in Medicare/Medicaid and suggesting an entrenched role in the regional oncology diagnostic market. This longevity supports the observed steady volume in specialized PET/CT services.
Across payers there are no extreme statistical outliers reported in the data: each of the top codes is described as “typical, unremarkable volume” or placed in mid-to-high percentiles rather than labeled extreme, which aligns with the center being a steady regional provider of PET/CT and radiopharmaceutical services rather than an anomalous billing outlier. The available rank/percentile annotations (e.g., Medicare 78815 at the 92nd percentile nationally and Medicaid 78815 at the 70th percentile in-state) support that interpretation.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 330 | $1,370 | $456.2K |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | 720 | $480 | $348.5K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 280 | $250 | $67.9K |
| 78816 | The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The… | 30 | $1,370 | $38.5K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 1,460 | $550 | $800.4K |
| 77336 | This code is for reporting ongoing medical physics consultation. When a patient is undergoing radiation treatment for a particular span of time with a number of therapy sessions every week, the… | 820 | $40 | $31.9K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1,270 | $20 | $30.5K |
| 77014 | N/A | 780 | $40 | $28.2K |
| 77334 | The provider designs, develops, and constructs special and customized devices for proper radiation dose delivery and protection of nearby healthy tissues. | 330 | $70 | $24.6K |
| 77300 | Radiation therapy is one of the most effective treatment methods for cancerous tumors. Due to its negative side effects like damage to the healthy cells, radiation therapy involves thorough planning… | 110 | $60 | $6.1K |
| 77280 | The provider uses a simulator or other imaging modality to determine the size and location of ports to be used for radiation therapy. This code describes a simple level service. | 20 | $50 | $1.3K |
How this provider's Medicaid billing volume and revenue compare to other Connecticut providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Connecticut median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 8 | 20 | 730 | $470 | $525K |
| 77334 | The provider designs, develops, and constructs special and customized devices for proper radiation dose delivery and protection of nearby healthy tissues. | 7 | 20 | 130 | $310 | $185K |
| 77336 | This code is for reporting ongoing medical physics consultation. When a patient is undergoing radiation treatment for a particular span of time with a number of therapy sessions every week, the… | 11 | 20 | 860 | $70 | $135.2K |
| 77300 | Radiation therapy is one of the most effective treatment methods for cancerous tumors. Due to its negative side effects like damage to the healthy cells, radiation therapy involves thorough planning… | 7 | 20 | 60 | $190 | $89.8K |
| 77280 | The provider uses a simulator or other imaging modality to determine the size and location of ports to be used for radiation therapy. This code describes a simple level service. | 8 | 10 | 80 | $80 | $27.7K |
| 77014 | N/A | 3 | 10 | 780 | $20 | $23.4K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 6 | 20 | 740 | $1 | $1.8K |
Other providers in the same ZIP code as The Harold Leever Regional Cancer Center Inc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.